top-banner

NEWS ROOM

Medicover Genetics’ MRD technology featured in NSCLC study at ESMO 2025

14 October 2025 - Medicover Genetics is pleased to announce new clinical data of its proprietary circulating tumor DNA-based minimal residual disease (MRD) assay will be featured in a poster presentation at the 2025 European Society for Medical Oncology (ESMO) Congress.

The poster presents additional results from the DART (Durvalumab After chemoRadioTherapy) study, conducted by Oslo University Hospital. The study focuses on patients with unresectable stage III non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy followed by durvalumab consolidation therapy. The study leverages Medicover Genetics’ ctDNA-based MRD assay, part of its liquid biopsy platform, to monitor residual disease through serial blood sampling during treatment and follow-up.

Attendees on behalf of Medicover Genetics include: Staffan Ternström, COO of Diagnostic Services, Medicover; Dr. Stefan C. Mehrle, Head of Medicover Genetics; and George Koumbaris, PhD, Scientific Director at Medicover Genetics Cyprus.

These findings further strengthen the growing body of clinical evidence supporting the utility and robustness of Medicover Genetics’ liquid biopsy MRD assay in oncology care.

The abstract (1819P) will be presented by Henrik Horndalsveen, Oslo Group, on Saturday, 18 October, from 12:00 to 12:45 in Hall 25.

For more information about the study, including the abstract, please visit https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal_2/presentation/list?q=1819P

OUR NETWORK